Immuno-Oncology Diagnostics Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2020 to 2024
254 Pages packed with information
“Explosion in immuno-oncology therapies creates an exploding diagnostic market. What is the impact of COVID-19?...”
Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. COVID-19 changes the focus.
This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.
A revolution in cancer therapy is underway. New therapy based on using the body’s natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.
The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
See the Table of Contents.
Send an email to us at email@example.com and we will happily email you a FREE copy of SAMPLE PAGES FROM THIS REPORT without any obligation on your part. And we will not pester you with phone calls!
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research and the American Association for Clinical Chemistry.
He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
B.Sc. (Chemistry) University of BC
M.B.A. (Finance and Policy) University of BC
Market Research - Burke Institute
Finance for Senior Executives - Harvard Business School